Swiss National Bank Has $43.34 Million Holdings in Illumina, Inc. $ILMN

Swiss National Bank lessened its holdings in Illumina, Inc. (NASDAQ:ILMN) by 4.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 456,300 shares of the life sciences company’s stock after selling 21,100 shares during the quarter. Swiss National Bank owned 0.30% of Illumina worth $43,335,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the business. Parkside Financial Bank & Trust grew its position in Illumina by 65.7% in the second quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company’s stock valued at $28,000 after purchasing an additional 115 shares in the last quarter. Quent Capital LLC bought a new stake in Illumina during the 3rd quarter worth about $29,000. Aster Capital Management DIFC Ltd bought a new stake in Illumina during the 3rd quarter worth about $33,000. Mather Group LLC. acquired a new position in shares of Illumina during the 3rd quarter worth about $46,000. Finally, Evelyn Partners Investment Management LLP boosted its stake in shares of Illumina by 4,927.3% during the 2nd quarter. Evelyn Partners Investment Management LLP now owns 553 shares of the life sciences company’s stock worth $49,000 after buying an additional 542 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Insider Activity

In other news, SVP Patricia Leckman sold 2,370 shares of Illumina stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $116.18, for a total transaction of $275,346.60. Following the completion of the transaction, the senior vice president directly owned 16,321 shares in the company, valued at approximately $1,896,173.78. The trade was a 12.68% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 2.60% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. Zacks Research downgraded Illumina from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, December 31st. Weiss Ratings reissued a “hold (c-)” rating on shares of Illumina in a research report on Monday, December 29th. Stifel Nicolaus boosted their price target on Illumina from $135.00 to $155.00 and gave the stock a “buy” rating in a research report on Tuesday, January 20th. JPMorgan Chase & Co. dropped their price objective on Illumina from $130.00 to $120.00 and set a “neutral” rating on the stock in a research note on Friday, February 6th. Finally, Barclays increased their price objective on Illumina from $100.00 to $110.00 and gave the company an “underweight” rating in a report on Monday, December 15th. Six equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $129.69.

Illumina Stock Down 4.9%

Shares of ILMN stock opened at $115.56 on Friday. Illumina, Inc. has a 52-week low of $68.70 and a 52-week high of $155.53. The stock has a market cap of $17.67 billion, a price-to-earnings ratio of 21.20, a PEG ratio of 2.32 and a beta of 1.45. The firm’s 50-day moving average is $133.45 and its 200-day moving average is $119.68. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.72 and a current ratio of 2.08.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, February 5th. The life sciences company reported $1.35 EPS for the quarter, topping analysts’ consensus estimates of $1.26 by $0.09. The business had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.10 billion. Illumina had a return on equity of 31.04% and a net margin of 19.57%.Illumina’s quarterly revenue was up 5.0% on a year-over-year basis. During the same quarter last year, the company posted $0.95 earnings per share. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. Sell-side analysts predict that Illumina, Inc. will post 4.51 EPS for the current year.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.